<DOC>
	<DOCNO>NCT01903200</DOCNO>
	<brief_summary>The objective study evaluate safety plasma concentration change quetiapine multiple oral administration FK949E ( extended-release formulation quetiapine ) elderly patient major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability FK949E Elderly Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosis major depressive disorder accord DSMIVTR ( Text Revision Diagnostic Statistical Manual Mental Disorders version4 ) criterion follow : In case receive antidepressant treatment : Patients diagnosis within 6 month prior provision write informed consent In case receive antidepressant treatment : Patients continuously receive antidepressant treatment time provide write informed consent Female patient childbearing potential negative serum pregnancy test result willing able use reliable method birth control study Patients could understand comply requirement study , judge investigator/subinvestigator A current past history DSMIVTR Axis I disorder major depressive disorder within 6 month prior study Diagnosis DSMIVTR Axis II disorder consider major impact patient 's current psychiatric status A history substance alcohol abuse dependence exclude caffeine nicotine Patients unable abstain drug induce inhibit drugmetabolizing enzyme CYP3A4 14 day prior start study drug administration throughout study period Patients show evidence sign renal hepatic failure , serious heart disease , cerebrovascular disease , viral hepatitis B C , acquire immunodeficiency syndrome ( AIDS ) ( carrier ) Patients diagnosis neurological condition , Parkinson 's disease , Huntington 's disease , essential tremor , multiple sclerosis , prior brain injury , space occupy lesion , etc . A clinical finding unstable ( e.g. , hypertension , unstable angina ) , opinion investigator subinvestigator , would negatively affect study medication would affect study medication A current diagnosis cancer ( except basal squamous cell skin carcinoma ) , unless remission least 5 year . Conditions could affect absorption metabolism study medication ( e.g. , malabsorption syndrome , liver disease ) . A current past diagnosis transient ischemic attack ( TIA ) A history seizure disorder , except febrile convulsion Receipt electroconvulsive therapy within 90 day prior start study drug administration Use depot antipsychotic injection inability drug period twice dose interval prior start study drug administration throughout study period Patients , investigator 's opinion , would require psychotherapy ( supportive psychotherapy ) study period , unless psychotherapy ongoing minimum 90 day study drug administration A score ≥ 3 HAMD17 Item ( suicide ) suicide attempt within past 6 month , judge serious suicidal homicidal risk opinion investigator/subinvestigator A current past history diabetes mellitus* glycated hemoglobin ( HbA1c ) ≥ 6.5 % screen within 2 month start study drug administration ( *refer guideline monitor blood glucose level patient treat atypical antipsychotic ) A white blood cell count ( WBC ) ≤ 3,000/mm3 screen assessment Elevation aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) value screen assessment ( grade 2 high accord `` Criteria Classification Grade Adverse Drug Reactions Pharmaceutical Products '' ( Pharmaceutical Affairs Bureau Safety Division 's Notification No . 80 issue 29 June 1992 ) ) A known history hypersensitivity quetiapine component FK949E tablet time provide write informed consent Treatment quetiapine depressive symptom bipolar disorder ( mania ) time provide write informed consent Participation another clinical study postmarketing study within 12 week prior start study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antipsychotic</keyword>
	<keyword>FK949E</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Elderly</keyword>
</DOC>